


## Anti-Wnt-5a antibody



**Description** 

Mouse monoclonal to Wnt-5a.

Model STJ98453

**Host** Mouse

**Reactivity** Human

**Applications** ELISA, IF, IHC, WB

**Immunogen** Purified recombinant fragment of Wnt-5a expressed in E. Coli.

**Gene ID** 7474

Gene Symbol WNT5A

**Dilution range** WB 1:500-1:2000IHC 1:200-1:1000IF 1:200-1:1000ELISA 1:10000

**Specificity** Wnt-5a Monoclonal Antibody detects endogenous levels of Wnt-5a protein.

**Tissue Specificity** Expression is increased in differentiated thyroid carcinomas compared to

normal thyroid tissue and anaplastic thyroid tumors where expression is low or undetectable. Expression is found in thyrocytes but not in stromal cells (at

protein level).

**Purification** Affinity purification

Clone ID 6F2

**Note** For Research Use Only (RUO).

**Protein Name** Protein Wnt-5a

**Clonality** Monoclonal

**Conjugation** Unconjugated

Isotype IgG1

**Formulation** Ascitic fluid containing 0.03% sodium azide.

**Storage Instruction** Store at -20°C, and avoid repeat freeze-thaw cycles.

Database Links <u>HGNC:12784OMIM:164975</u>

**Alternative Names** Protein Wnt-5a

**Function** Ligand for members of the frizzled family of seven transmembrane receptors.

Can activate or inhibit canonical Wnt signaling, depending on receptor context. In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves

down-regulation of beta-catenin-induced reporter gene expression.

Suppression of the canonical pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration. Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells. Required during embryogenesis for extension of the primary anterior-posterior axis and for outgrowth of limbs and the genital tubercle. Inhibits type II collagen

expression in chondrocytes.

**Cellular Localization** Secreted, extracellular space, extracellular matrix.

Post-translational Modifications

Glycosylation is necessary for secretion but not for activity. Palmitoleylation is required for efficient binding to frizzled receptors. Depalmitoleylation leads to Wnt signaling pathway inhibition. Proteolytic processing by TIKI1 and TIKI2 promotes oxidation and formation of large disulfide-bond oligomers,

leading to inactivation of WNT5A.

St John's Laboratory Ltd

**F** +44 (0)207 681 2580

T +44 (0)208 223 3081

W http://www.stjohnslabs.com/ E info@stjohnslabs.com